Effect of Tropical Bromefenac in the Treatment of Central Serous Chorioretinopathy: A Study of 32 Cases
Journal Title: Journal of Indus Medical College - Year 2018, Vol 1, Issue 1
Abstract
Purpose: To monitor and confirm the effect of topical bromfenac nonsteroidal anti-inflammatory drug (NSAID) in the treatment of acute central serous chorioretinopathy at our facility. Introduction: Central serous chorioretinopathy, a disorder mostly an idiopathic ocular disorder characterized by a serous detachment of the neurosensory retina at the macula, caused by active retinal pigment epithelial leakage. Although the exact pathophysiology of CSC has not been clearly elucidated, the primary abnormality leading to RPE disruption and leakage is thought to cause increase choroidal permeability. Studies using different imaging techniques have revealed the possible causes of abnormal permeability of the inner choroid. Ischemia and inflammation might lead to exudative changes within the choroid and the subsequent changes at the RPE. Topical bromfenac, ketorolac, nepafenac and diclofenac all belong to the NSAIDs class of medications. As an anti-inflammatory class, they function by inhibiting the enzyme cyclooxygenase, which blocks the synthesis of prostaglandins. A reduction in prostaglandin formation results a decrease in inflammation. It appears that the principle pathway involved in pain and inflammation is the cycloxygenase-2 pathway where nonsteroidal anti-inflammatory drugs (NSAIDs) seems to play a significant role. Materials and Methods: It is an interventional, retrospective as well as prospective study conducted at Indus Medical College Hospital, Tando Mohammad Khan from February 2017 to January 2018 includes 32 patients. Only patients with acute CSC were included while those with chronic or recurrence were excluded. Careful history taken about sensitivity to bromfenac or any other non-steroidal anti-inflammatory drugs (NSAIDs). All 32 patients were diagnosed as having acute CSC relying upon visual acuity by standard Snellen chart, dilated fundus exam using slit lamp (SHIN-NIPPON SL-203, Japan) with 90D lens and OCT (ocular coherence tomography by NIDEK, model RS-330 Japan) findings. All patients were treated by bromfenac topical drops twice daily. Patients followed on 5th day, 10th day and 30th day after presentation. Vision was recorded, dilated fundoscopy and OCT performed on each visit. All 32 patients were male (Table 1), divided into 3 age groups i.e. group A(21-30 yrs) includes 16 (50%) patients, group B(31- 40 yrs) includes 12(37.50%) patients and group C (41-50 yrs) includes 4(12.50%) patient (Table 2). 14(43.75%) were right eyes, 18(56.25%) were left (Table 3). Vision recorded using standard Snellen chart, 16(50%) patients having vision 0.4, 8(25%) were 0.2, 5(15.62%) were having 0.1 while remaining 3(9.37%) were recorded as CF at 1 meter (Table 4). Macular thickness recorded using OCT, patients again divided into 3 groups on OCT findings, group 1, 18(56.25%) patients having macular thickness between 422-485 microns, group 2, 11(34.37%) patients between 535-565 microns, while group 3 includes 3(9.37%) patients having thickness between 657-722 microns (Table 5). All 32 patients received topical bromfenac, one drop twice daily to treat acute CSC for 10 days and monitor for 1 month. Results: This interventional study includes 32 patients who were diagnosed as acute CSC and followed from the day of presentation to 30th day. All 32 patients were underwent intervention by using topical bromfenac eye drop, one drop twice daily for 30 days. Macular thickness and visual acuity recorded from the day of presentation up to 30th day. Table 6 shows all changes before and after treatment and Figure 1 (a, b, c, d) and 2 (a, b, c, d) shows early resolution of sub-macular fluid in one of these patients treated with topical bromfenac eye drops (one drop twice daily). In group A the macular thickness (CFT) improve from 422-485 microns at onset to 317-382 microns on 5th day becomes 246-295 on 10th day while 210-226 on 30th day. Vision improved from 0.4 to 0.7 at 5th day, improved to 0.8 on 10th day and remained same on 30th day. In group B the CFT reduced from 535-565 microns to 401-440 microns on 5th day becomes 318-310 on 10th day and on 30th day it was 221-232 microns with improvement in visual acuity which was 0.2 at onset to 0.6 at 5th day, 0.7 at 10th day and improved to 0.8 on 30th day. In group C the CFT reduced from 657-722 microns to 456-469 microns on 5th day, 259-366 microns on 10th day while 206-227 microns on 30th day. Visual acuity improved from CF at onset to 0.4 on 5th day, 0.6 on 10th day and improved to 0.7 on 30th day. Conclusion: This, simple, safe, affordable and easily available treatment modality in all parts of the world with early rehabilitation of acute CSC patients.
Authors and Affiliations
Nisar Ahmed Khan, Aisha Khan, Atiqa Khan, Sobia Khan, Aftab Ahmed Khan
Keywords
Related Articles
- EP ID EP690395
- DOI -
- Views 162
- Downloads 0
Co-Existence of Malaria With Thrombocytopenia
BACKGROUND: Malaria, especially in developing countries, is an important health problem. It is significant cause of mortality and morbidity, particularly in tropics. In this specific disorder, there are many haematologic...
Molecular Diagnosis – A Game Changer
Successful care rendered by a healthcare professional to the patient relies on specific 'diagnosis' and 'treatment' of the ailment. For decades, first-line laboratory diagnostic applications such as Gram staining, staini...
Recent Advances In Diagnosis of Thalassemia
Mutations and/or deletions in the α-globin or β-globin genes cause hereditary hemoglobin disorders. Thalassemia is caused by haemoglobin structural abnormalities due to quantitative abnormalities, and hemoglobinopathies....
Diagnostic Significance of Platelet – to – Lymphocyte Ratio in Evaluation of Sepsis
Introduction: Sepsis is one the major cause of mortality and mortality in hospital settings. Many inflammatory markers have been proposed but their use is often limited due to unavailability and cost. Platelet – to – ly...
Hypomagnesaemia In Diabetes Mellitus Type 2
Introduction: Patients of diabetes mellitus type 2 have insufficiency of many important elements including serum magnaesium. Hypomagnesaemia is related with complications of diabetes mellitus and amplified the duration o...